DiscoverOncLive® On AirS14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Update: 2025-09-12
Share

Description

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).
Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

OncLive® On Air